-
公开(公告)号：US07101872B2
公开(公告)日：2006-09-05
申请号：US10762107
申请日：2004-01-21
IPC分类号： C07D243/10 , A61K31/55
CPC分类号： C12N9/93 , A61K38/00 , C07D243/38 , C07D405/06 , C07D405/14 , C12N9/0004 , C12N9/10 , C12N9/12 , C12N9/14 , C12N9/88 , C12N9/90 , C12N15/52 , C12P17/10 , C12R1/29 , Y02A50/473
摘要： This invention relates to a novel farnesylated dibenzodiazepinone, named ECO-04601, its pharmaceutically acceptable salts and derivatives, and to methods for obtaining such compounds. One method of obtaining the ECO-04601 compound is by cultivation of a novel strain of Micromonospora sp., 046-ECO11; another method involves expression of biosynthetic pathway genes in transformed host cells. The present invention further relates to Micromonospora sp. strain 046-ECO11, to the use of ECO-04601 and its pharmaceutically acceptable salts and derivatives as pharmaceuticals, in particular to their use as inhibitors of cancer cell growth, bacterial cell growth, mammalian lipoxygenase, and to pharmaceutical compositions comprising ECO-04601 or a pharmaceutically acceptable salt or derivative thereof. Finally, the invention relates to novel polynucleotide sequences and their encoded proteins, which are involved in the biosynthesis of ECO-04601.
摘要翻译： 本发明涉及名为ECO-04601的新型法呢基化二苯并二氮杂酮，其药学上可接受的盐和衍生物，以及获得这些化合物的方法。 获得ECO-04601化合物的一种方法是通过培养一种新型的小单孢菌属菌株046-ECO11; 另一种方法涉及在转化的宿主细胞中表达生物合成途径基因。 本发明还涉及小单孢菌属 应用046-ECO11，使用ECO-04601及其药学上可接受的盐和衍生物作为药物，特别是其作为癌细胞生长抑制剂，细菌细胞生长，哺乳动物脂氧合酶的用途，以及包含ECO-04601或 其药学上可接受的盐或衍生物。 最后，本发明涉及参与ECO-04601的生物合成的新型多核苷酸序列及其编码的蛋白质。
-
公开(公告)号：US20080199940A1
公开(公告)日：2008-08-21
申请号：US11511586
申请日：2006-08-28
CPC分类号： C12N9/93 , A61K38/00 , C07D243/38 , C07D405/06 , C07D405/14 , C12N9/0004 , C12N9/10 , C12N9/12 , C12N9/14 , C12N9/88 , C12N9/90 , C12N15/52 , C12P17/10 , C12R1/29 , Y02A50/473
摘要： This invention relates to a novel farnesylated dibenzodiazepinone, named ECO-04601, its pharmaceutically acceptable salts and derivatives, and to methods for obtaining such compounds. One method of obtaining the ECO-04601 compound is by cultivation of a novel strain of Micromonospora sp., 046-ECO11; another method involves expression of biosynthetic pathway genes in transformed host cells. The present invention further relates to Micromonospora sp. strain 046-ECO11, to the use of ECO-04601 and its pharmaceutically acceptable salts and derivatives as pharmaceuticals, in particular to their use as inhibitors of cancer cell growth, bacterial cell growth, mammalian lipoxygenase, and to pharmaceutical compositions comprising ECO-04601 or a pharmaceutically acceptable salt or derivative thereof. Finally, the invention relates to novel polynucleotide sequences and their encoded proteins, which are involved in the biosynthesis of ECO-04601.
摘要翻译： 本发明涉及名为ECO-04601的新型法呢基化二苯并二氮杂酮，其药学上可接受的盐和衍生物，以及获得这些化合物的方法。 获得ECO-04601化合物的一种方法是通过培养一种新型的小单孢菌属菌株046-ECO11; 另一种方法涉及在转化的宿主细胞中表达生物合成途径基因。 本发明还涉及小单孢菌属 应用046-ECO11，使用ECO-04601及其药学上可接受的盐和衍生物作为药物，特别是其作为癌细胞生长抑制剂，细菌细胞生长，哺乳动物脂氧合酶的用途，以及包含ECO-04601或 其药学上可接受的盐或衍生物。 最后，本发明涉及参与ECO-04601的生物合成的新型多核苷酸序列及其编码的蛋白质。
-
公开(公告)号：US20100204468A1
公开(公告)日：2010-08-12
申请号：US12764537
申请日：2010-04-21
申请人： Faustinus YEBOAH , Mahmood PIRAEE
发明人： Faustinus YEBOAH , Mahmood PIRAEE
IPC分类号： C07D243/10 , C12P17/10 , C12N1/00 , C12N1/20
CPC分类号： C12P17/10 , B01D15/00 , B01D61/145 , C07D243/38 , C12N1/20 , C12P17/12 , C12R1/29
摘要： The present invention provides a scalable process for producing a concentrate containing a mass of a farnesylated dibenzodiazepinone by fermenting in an aqueous culture medium a strain of a microorganism that is capable of producing the farnesylated dibenzodiazepinone, upon completion of fermentation harvesting the fermentation broth and extracting the fermentation broth to provide an extract, and thereafter treating the extract to form the concentrate. The concentrate so produced may be utilized in downstream processes for producing pharmaceutical compounds. A strain of a Micromonospora species capable of producing a farnesylated dibenzodiazepinone at a high yield rate is provided, together with culture media for culturing microorganisms, and fermentation conditions for production of the farnesylated dibenzodiazepinone of the concentrate.
摘要翻译： 本发明提供了一种可扩展的方法，用于生产含有大量法呢基化二苯并二氮杂酮的浓缩物，其通过在水性培养基中发酵能够产生法呢基化二苯并二氮杂酮的微生物菌株，在完成发酵收获发酵液并提取 发酵液提供提取物，然后处理提取物以形成浓缩物。 如此生产的浓缩物可用于生产药物化合物的下游方法。 提供能够以高产率生产法呢基化二苯并二氮杂酮的小单孢菌属菌株，以及用于培养微生物的培养基和用于生产浓缩物的法呢基化二苯并二氮杂酮的发酵条件。
-
4.发明申请Farnesyl dibenzodiazepinone, processes for its production and its use as a pharmaceutical 有权法呢基二苯并二氮杂酮，其生产方法及其用作药物公开(公告)号：US20050043297A1
公开(公告)日：2005-02-24
申请号：US10762107
申请日：2004-01-21
IPC分类号： A61K38/00 , C07D243/38 , C12N9/00 , C12N9/02 , C12N9/10 , C12N9/12 , C12N9/14 , C12N9/88 , C12N9/90 , C12N15/52 , C12P17/10 , A61K31/551 , C07D243/10
CPC分类号： C12N9/93 , A61K38/00 , C07D243/38 , C07D405/06 , C07D405/14 , C12N9/0004 , C12N9/10 , C12N9/12 , C12N9/14 , C12N9/88 , C12N9/90 , C12N15/52 , C12P17/10 , C12R1/29 , Y02A50/473
摘要： This invention relates to a novel farnesylated dibenzodiazepinone, named ECO-04601, its pharmaceutically acceptable salts and derivatives, and to methods for obtaining such compounds. One method of obtaining the ECO-04601 compound is by cultivation of a novel strain of Micromonospora sp., 046-ECO11; another method involves expression of biosynthetic pathway genes in transformed host cells. The present invention further relates to Micromonospora sp. strain 046-ECO11, to the use of ECO-04601 and its pharmaceutically acceptable salts and derivatives as pharmaceuticals, in particular to their use as inhibitors of cancer cell growth, bacterial cell growth, mammalian lipoxygenase, and to pharmaceutical compositions comprising ECO-04601 or a pharmaceutically acceptable salt or derivative thereof. Finally, the invention relates to novel polynucleotide sequences and their encoded proteins, which are involved in the biosynthesis of ECO-04601.
摘要翻译： 本发明涉及名为ECO-04601的新型法呢基化二苯并二氮杂酮，其药学上可接受的盐和衍生物，以及获得这些化合物的方法。 获得ECO-04601化合物的一种方法是通过培养一种新型的小单孢菌属菌株046-ECO11; 另一种方法涉及在转化的宿主细胞中表达生物合成途径基因。 本发明还涉及小单孢菌属 应用046-ECO11，使用ECO-04601及其药学上可接受的盐和衍生物作为药物，特别是其作为癌细胞生长抑制剂，细菌细胞生长，哺乳动物脂氧合酶的用途，以及包含ECO-04601或 其药学上可接受的盐或衍生物。 最后，本发明涉及参与ECO-04601的生物合成的新型多核苷酸序列及其编码的蛋白质。
-
5.发明申请公开(公告)号：US20200281944A1
公开(公告)日：2020-09-10
申请号：US16764088
申请日：2018-11-15
申请人： Mahmood Piraee
发明人： Mahmood Piraee
IPC分类号： A61K31/58 , C07J41/00 , C07J43/00 , C07J33/00 , C07J51/00 , C07J31/00 , C07J9/00 , A61K31/575 , A61K31/16 , A61K31/198 , A61K31/4164
摘要： Novel lanosterol derivatives and novel 25-hydroxycholesterol derivatives including their pharmaceutically acceptable salts as well as methods of treatment and pharmaceutical compositions and formulations of lanosterol and derivatives thereof and 25-hydroxycholesterol and derivatives thereof useful in treating ophthalmic disorders including cataracts and presbyopia.
-
公开(公告)号：US09486464B2
公开(公告)日：2016-11-08
申请号：US13819173
申请日：2011-08-25
申请人： Mahmood Piraee
发明人： Mahmood Piraee
IPC分类号： A61K31/7024 , A61K31/05 , A61K36/88 , A61K31/047 , A61K31/122 , A61K31/202 , A61K31/355 , A61K31/375 , A61K31/59 , A61K33/30 , A61K33/34
CPC分类号： A61K36/88 , A23L33/105 , A23L33/15 , A23L33/16 , A61K31/05 , A61K2300/00
摘要： A dietary supplement composition includes a synergistic combination of saffron and resveratrol for providing anti-oxidant and gene modulation effects for preventing, ameliorating and/or reducing a rate of development and progression of age-related macular degeneration (AMD). Optionally, the combination is supplemented with one or more further ingredients: fish oil, Zinc, Copper, vitamin C, vitamin E, lutein, zeaxanthin. The combination is beneficially provided as a composition which is useful for reducing a risk of developing, and/or for reducing a rate of progression of age-related macular degeneration, and/or for preventing age-related sight loss, and other age-related diseases.
摘要翻译： 膳食补充剂组合物包括藏红花和白藜芦醇的协同组合，用于提供用于预防，改善和/或降低年龄相关性黄斑变性（AMD）的发展和进展的速率的抗氧化剂和基因调节效应。 任选地，组合补充有一种或多种其它成分：鱼油，锌，铜，维生素C，维生素E，叶黄素，玉米黄质。 该组合有益地作为一种组合物提供，该组合物可用于降低发生和/或降低年龄相关性黄斑变性进展的风险和/或用于预防与年龄有关的视力丧失的风险，以及其他年龄相关 疾病
-
7.发明授权公开(公告)号：US08361759B2
公开(公告)日：2013-01-29
申请号：US12764537
申请日：2010-04-21
申请人： Faustinus Yeboah , Mahmood Piraee
发明人： Faustinus Yeboah , Mahmood Piraee
IPC分类号： C12P17/10
CPC分类号： C12P17/10 , B01D15/00 , B01D61/145 , C07D243/38 , C12N1/20 , C12P17/12 , C12R1/29
摘要： The present invention provides a scalable process for producing a concentrate containing a mass of a farnesylated dibenzodiazepinone by fermenting in an aqueous culture medium a strain of a microorganism that is capable of producing the farnesylated dibenzodiazepinone, upon completion of fermentation harvesting the fermentation broth and extracting the fermentation broth to provide an extract, and thereafter treating the extract to form the concentrate. The concentrate so produced may be utilized in downstream processes for producing pharmaceutical compounds. A strain of a Micromonospora species capable of producing a farnesylated dibenzodiazepinone at a high yield rate is provided, together with culture media for culturing microorganisms, and fermentation conditions for production of the farnesylated dibenzodiazepinone of the concentrate.
摘要翻译： 本发明提供了一种可扩展的方法，用于生产含有大量法呢基化二苯并二氮杂酮的浓缩物，其通过在水性培养基中发酵能够产生法呢基化二苯并二氮杂酮的微生物菌株，在完成发酵收获发酵液并提取 发酵液提供提取物，然后处理提取物以形成浓缩物。 如此生产的浓缩物可用于生产药物化合物的下游方法。 提供能够以高产率生产法呢基化二苯并二氮杂酮的小单孢菌属菌株，以及用于培养微生物的培养基和用于生产浓缩物的法呢基化二苯并二氮杂酮的发酵条件。
-
公开(公告)号：US20130156746A1
公开(公告)日：2013-06-20
申请号：US13819173
申请日：2011-08-25
申请人： Mahmood Piraee
发明人： Mahmood Piraee
IPC分类号： A61K31/7024 , A61K31/375 , A61K31/202 , A61K31/122 , A61K31/59 , A61K33/30 , A61K33/34 , A61K31/355 , A61K31/05 , A61K31/047
CPC分类号： A61K36/88 , A23L33/105 , A23L33/15 , A23L33/16 , A61K31/05 , A61K2300/00
摘要： A dietary supplement composition includes a synergistic combination of saffron and resveratrol for providing anti-oxidant and gene modulation effects for preventing, ameliorating and/or reducing a rate of development and progression of age-related macular degeneration (AMD). Optionally, the combination is supplemented with one or more further ingredients: fish oil, Zinc, Copper, vitamin C, vitamin E, lutein, zeaxanthin. The combination is beneficially provided as a composition which is useful for reducing a risk of developing, and/or for reducing a rate of progression of age-related macular degeneration, and/or for preventing age-related sight loss, and other age-related diseases.
摘要翻译： 膳食补充剂组合物包括藏红花和白藜芦醇的协同组合，用于提供用于预防，改善和/或降低年龄相关性黄斑变性（AMD）的发展和进展的速率的抗氧化剂和基因调节效应。 任选地，组合补充有一种或多种其它成分：鱼油，锌，铜，维生素C，维生素E，叶黄素，玉米黄质。 该组合有益地作为一种组合物提供，该组合物可用于降低发生和/或降低年龄相关性黄斑变性进展的风险和/或用于预防与年龄有关的视力丧失的风险，以及其他年龄相关 疾病
-
9.发明授权Cyclic hexadepsipeptides, processes for their production and their use as pharmaceuticals 失效环十六肽，其制备方法及其作为药物的用途公开(公告)号：US08076287B2
公开(公告)日：2011-12-13
申请号：US12294213
申请日：2007-03-28
IPC分类号： A61K38/12
CPC分类号： C07K7/06 , A61K38/00 , C12P17/188 , C12P21/02 , C12R1/465
摘要： The present invention provides cyclic hexadepsipeptides and their pharmaceutically acceptable salts, solvates and prodrugs, and methods for obtaining the compounds, by fermentation, optionally followed by post-biosynthesis chemical modification. The present invention further provides uses of cyclic hexadepsipeptides, and their pharmaceutically acceptable salts, solvates and prodrugs as pharmaceuticals, in particular to their use as antibacterial, antifungal or antineoplastic agents, and to pharmaceutical compositions comprising a cyclic hexadepsipeptide, or a pharmaceutically acceptable salt, solvate or prodrug thereof, together with a carrier.
摘要翻译： 本发明提供环状十六肽及其药学上可接受的盐，溶剂合物和前药，以及通过发酵，任选地随后进行生物合成化学修饰来获得化合物的方法。 本发明进一步提供了环状十六肽及其药学上可接受的盐，溶剂合物和前药作为药物，特别是其作为抗细菌剂，抗真菌剂或抗肿瘤剂的用途的用途，以及包含环十六肽或其药学上可接受的盐， 溶剂化物或前药，以及载体。
-
10.发明申请CYCLIC HEXADEPSIPEPTIDES, PROCESSES FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS 失效周期性十六烷基硫酸酯，其生产工艺及其作为药物的使用公开(公告)号：US20090215789A1
公开(公告)日：2009-08-27
申请号：US12294213
申请日：2007-03-28
IPC分类号： A61K31/501 , C07D401/14 , C12N1/20 , C12P17/16 , A61P31/04 , A61P35/00
CPC分类号： C07K7/06 , A61K38/00 , C12P17/188 , C12P21/02 , C12R1/465
摘要： The present invention provides cyclic hexadepsipeptides and their pharmaceutically acceptable salts, solvates and prodrugs, and methods for obtaining the compounds, by fermentation, optionally followed by post-biosynthesis chemical modification. The present invention further provides uses of cyclic hexadepsipeptides, and their pharmaceutically acceptable salts, solvates and prodrugs as pharmaceuticals, in particular to their use as antibacterial, antifungal or antineoplastic agents, and to pharmaceutical compositions comprising a cyclic hexadepsipeptide, or a pharmaceutically acceptable salt, solvate or prodrug thereof, together with a carrier.
摘要翻译： 本发明提供环状十六肽及其药学上可接受的盐，溶剂合物和前药，以及通过发酵，任选地随后进行生物合成化学修饰来获得化合物的方法。 本发明进一步提供了环状十六肽及其药学上可接受的盐，溶剂合物和前药作为药物，特别是其作为抗细菌剂，抗真菌剂或抗肿瘤剂的用途的用途，以及包含环十六肽或其药学上可接受的盐， 溶剂化物或前药，以及载体。
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.021 秒)
